CY1112154T1 - Μεθοδος για την παρασκευη ξηραμενων με ψεκασμο φαρμακοτεχνικων μορφων της tmc125 - Google Patents

Μεθοδος για την παρασκευη ξηραμενων με ψεκασμο φαρμακοτεχνικων μορφων της tmc125

Info

Publication number
CY1112154T1
CY1112154T1 CY20111101185T CY111101185T CY1112154T1 CY 1112154 T1 CY1112154 T1 CY 1112154T1 CY 20111101185 T CY20111101185 T CY 20111101185T CY 111101185 T CY111101185 T CY 111101185T CY 1112154 T1 CY1112154 T1 CY 1112154T1
Authority
CY
Cyprus
Prior art keywords
tmc125
dryers
pharmaceutical forms
preparing pharmaceutical
spray
Prior art date
Application number
CY20111101185T
Other languages
English (en)
Inventor
Filip Rene Irene Kiekens
Jody Firmin Marceline Voorspoels
Lieven Elvire Colette Baert
Original Assignee
Tibotec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37179187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112154(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals filed Critical Tibotec Pharmaceuticals
Publication of CY1112154T1 publication Critical patent/CY1112154T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση αυτή αφορά μια μέθοδο για την παραγωγή μιας ξηραμένης με ψεκασμό σκόνης η οποία αποτελείται από μικροκρυσταλλική κυτταρίνη σε μια στερεή διασπορά της αντι-HIV ένωσης ετραβιρίνης (TMC125) σε ένα υδατοδιαλυτό πολυμερές.
CY20111101185T 2006-06-06 2011-11-30 Μεθοδος για την παρασκευη ξηραμενων με ψεκασμο φαρμακοτεχνικων μορφων της tmc125 CY1112154T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06115029 2006-06-06
EP07729974A EP2029110B1 (en) 2006-06-06 2007-06-06 Process for preparing spray dried formulations of tmc125

Publications (1)

Publication Number Publication Date
CY1112154T1 true CY1112154T1 (el) 2015-12-09

Family

ID=37179187

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101185T CY1112154T1 (el) 2006-06-06 2011-11-30 Μεθοδος για την παρασκευη ξηραμενων με ψεκασμο φαρμακοτεχνικων μορφων της tmc125

Country Status (27)

Country Link
US (2) US20090197903A1 (el)
EP (1) EP2029110B1 (el)
JP (1) JP5089685B2 (el)
KR (1) KR101179905B1 (el)
CN (1) CN101453989B (el)
AT (1) ATE522202T1 (el)
AU (1) AU2007255418C1 (el)
BR (1) BRPI0712346B8 (el)
CA (1) CA2651665C (el)
CY (1) CY1112154T1 (el)
DK (1) DK2029110T3 (el)
EC (1) ECSP088938A (el)
ES (1) ES2372983T3 (el)
HK (1) HK1129579A1 (el)
HR (1) HRP20110883T1 (el)
IL (1) IL195710A (el)
ME (1) ME01305B (el)
MX (1) MX2008015686A (el)
NO (1) NO343652B1 (el)
NZ (1) NZ572702A (el)
PL (1) PL2029110T3 (el)
PT (1) PT2029110E (el)
RS (1) RS52053B (el)
RU (1) RU2406502C2 (el)
SI (1) SI2029110T1 (el)
WO (1) WO2007141308A1 (el)
ZA (1) ZA200810345B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2263671B1 (en) * 2008-04-02 2016-07-20 Astellas Pharma Inc. Amide derivative-containing pharmaceutical composition
WO2010006697A2 (en) * 2008-06-30 2010-01-21 Tibotec Pharmaceuticals Powders for reconstitution
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
JP6301339B2 (ja) * 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
JP2021523976A (ja) * 2018-05-11 2021-09-09 サムヤン コーポレイション 固体分散体、その製造方法、それを用いる鎖延長ポリウレタン及びそれを含むエポキシ樹脂組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2920956B2 (ja) * 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
CZ301367B6 (cs) 1998-11-10 2010-02-03 Janssen Pharmaceutica N. V. Derivát pyrimidinu, zpusob a meziprodukty pro jeho prípravu a lécivo pro lécení HIV na jeho bázi
DE60039379D1 (de) * 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
BR0307515A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ATE353633T1 (de) * 2002-12-19 2007-03-15 Pharmacia Corp Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
CN1822843B (zh) * 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
JP2007513937A (ja) * 2003-12-09 2007-05-31 ファイザー インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤を含む組成物

Also Published As

Publication number Publication date
EP2029110A1 (en) 2009-03-04
JP2009539804A (ja) 2009-11-19
CN101453989A (zh) 2009-06-10
AU2007255418A1 (en) 2007-12-13
PL2029110T3 (pl) 2012-03-30
RS52053B (en) 2012-04-30
WO2007141308A1 (en) 2007-12-13
SI2029110T1 (sl) 2012-01-31
PT2029110E (pt) 2011-11-23
HRP20110883T1 (hr) 2012-01-31
DK2029110T3 (da) 2011-12-19
AU2007255418C1 (en) 2011-08-18
NZ572702A (en) 2011-09-30
CA2651665A1 (en) 2007-12-13
JP5089685B2 (ja) 2012-12-05
NO20090061L (no) 2009-01-06
IL195710A0 (en) 2009-09-01
CA2651665C (en) 2010-04-27
KR101179905B1 (ko) 2012-09-07
CN101453989B (zh) 2012-06-13
HK1129579A1 (en) 2009-12-04
ZA200810345B (en) 2012-05-30
EP2029110B1 (en) 2011-08-31
AU2007255418B2 (en) 2010-12-23
BRPI0712346B1 (pt) 2020-09-29
ME01305B (me) 2012-04-30
ECSP088938A (es) 2009-01-30
MX2008015686A (es) 2009-01-12
IL195710A (en) 2014-02-27
RU2406502C2 (ru) 2010-12-20
ES2372983T3 (es) 2012-01-30
BRPI0712346A2 (pt) 2012-07-17
US9603803B2 (en) 2017-03-28
RU2008152411A (ru) 2010-07-20
NO343652B1 (no) 2019-04-29
US20120208834A1 (en) 2012-08-16
BRPI0712346B8 (pt) 2021-05-25
ATE522202T1 (de) 2011-09-15
US20090197903A1 (en) 2009-08-06
KR20090024131A (ko) 2009-03-06

Similar Documents

Publication Publication Date Title
CY1112154T1 (el) Μεθοδος για την παρασκευη ξηραμενων με ψεκασμο φαρμακοτεχνικων μορφων της tmc125
MX2012007676A (es) Nueva formulacion de anticuerpo.
EA200970580A1 (ru) Таннат разагилина
WO2010031720A3 (en) Novel antibody formulation
WO2012056111A3 (en) Drug delivery compositions
WO2009100995A3 (de) Lagerstabile produktsysteme für prämixformulierungen
DK2107913T3 (da) Anvendelse af thiolerede polysaccharider til vævsopbygning
UA86731C2 (ru) Делимая галеновая форма модифицированного высвобождения активного ингредиента
WO2009121501A3 (de) Partikel, erhältlich durch trocknung einer wässrigen nanoharnstoff-dispersion
WO2011045817A3 (en) Process for the preparation of fosaprepitant
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
GB201303865D0 (en) Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
MX2010009931A (es) Proceso para la preparacion de 2-amino-2-[2-(4-c3-c21-alquil-fenil )-etil]-propano-1,3-dioles.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
UA96627C2 (ru) Сухой экстракт из pelargonium sidoides ta pelargonium reniforme, способ его получения и продукты на его основе
WO2009010377A3 (en) Process for preparing platelet-like (embossed) particles
WO2009049820A3 (de) Amorphe formulierung
FI20085526A (fi) Menetelmä pigmenttituotteen muodostamiseksi selluloosajohdannaisesta
WO2014128728A3 (en) Solid forms of cabazitaxel and processes for preparation thereof
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2012016707A3 (en) Oral dosage form for the modified release of dimebolin
TW200738135A (en) Plant growth mediator having chitosan and chorophyll generating accelerator and the manufacturing method thereof